Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021

IntroductionFew population-based studies have examined associations between psychedelic use and mental health outcomes. This work describes characteristics of exclusive psychedelic mushroom use (referred to as PM use), PMs in combination with other psychedelic substances (multi-psychedelic or MP) us...

Full description

Saved in:
Bibliographic Details
Main Authors: Sofia Abramsky-Sze, Elliot Marseille, Richard Matzopoulos, Robert Morlock, Leonard Lerer
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1508811/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850070972439199744
author Sofia Abramsky-Sze
Elliot Marseille
Richard Matzopoulos
Richard Matzopoulos
Robert Morlock
Leonard Lerer
author_facet Sofia Abramsky-Sze
Elliot Marseille
Richard Matzopoulos
Richard Matzopoulos
Robert Morlock
Leonard Lerer
author_sort Sofia Abramsky-Sze
collection DOAJ
description IntroductionFew population-based studies have examined associations between psychedelic use and mental health outcomes. This work describes characteristics of exclusive psychedelic mushroom use (referred to as PM use), PMs in combination with other psychedelic substances (multi-psychedelic or MP) use, and non-psychedelic use and explores mental health ratings in non-clinical settings.MethodsThis work uses cross-sectional survey data from American adults collected by Acumen Health Research Institute, including demographic characteristics, general health-related quality of life (Veterans RAND derived mental and physical health composite scores), depression (PHQ 9-item), anxiety (GAD 7-item), comorbid conditions (CCI), health resource utilization, and perceptions, knowledge, and use of psychedelics. Multivariate and descriptive statistics were used to describe participant characteristics. Correlation analysis assessed anxiety and depression scores across groups. Mean anxiety and depression scores were compared using ANOVA and Tukey’s HSD. A multivariate linear regression model controlling for past-year depression, past-year anxiety, age, region, ethnicity, sex, educational attainment, employment, and psychedelic use predicted mental health composite scores (MCS).ResultsOf the 6,869 participants included in the dataset, 256 (3.7%) reported using psychedelics in the last 12 months. Of those using psychedelics, 122 (47.7%) reported PM use and 134 (52.3%) reported MP use. All psychedelic users reported lower MCS and higher levels of anxiety and depression relative to non-users (those who said they had not used psychedelics in the past year). The lowest mental health scores were reported in the MP users followed by the PM users (higher MCS corresponded to better mental health). When controlling for confounding characteristics including past-year anxiety and depression, disparities in mental health scores persisted between those with any psychedelic use and the non-psychedelic group (p<0.001).ConclusionThis paper extends previous work describing the association between psychedelic use and mental health, controlling for confounding mental health factors such as comorbid anxiety and depression. These results suggest psychedelic users may have poorer mental health than their non-using counterparts in certain contexts and emphasize the need for future research in this field. Both non-adjusted and adjusted analyses demonstrate lower mental health scores for PM and MP users relative to non-psychedelic users. These differential effects highlight the need for further detailed, population-based research on the use of exclusive psilocybin and on psychedelics in combination.
format Article
id doaj-art-3b963bf0d155464dbf2705c20e951fd7
institution DOAJ
issn 1664-0640
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Psychiatry
spelling doaj-art-3b963bf0d155464dbf2705c20e951fd72025-08-20T02:47:24ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402025-03-011610.3389/fpsyt.2025.15088111508811Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021Sofia Abramsky-Sze0Elliot Marseille1Richard Matzopoulos2Richard Matzopoulos3Robert Morlock4Leonard Lerer5Collaborative for the Economics of Psychedelics, University of California, Berkeley, Berkeley, CA, United StatesCollaborative for the Economics of Psychedelics, University of California, Berkeley, Berkeley, CA, United StatesDivision of Public Health Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South AfricaBurden of Disease Research Unit, South African Medical Research Council, Cape Town, South AfricaYourCareChoice, Ann Arbor, MI, United StatesBack of the Yards Algae Sciences - Parow Entheobiosciences, Chicago, IL, United StatesIntroductionFew population-based studies have examined associations between psychedelic use and mental health outcomes. This work describes characteristics of exclusive psychedelic mushroom use (referred to as PM use), PMs in combination with other psychedelic substances (multi-psychedelic or MP) use, and non-psychedelic use and explores mental health ratings in non-clinical settings.MethodsThis work uses cross-sectional survey data from American adults collected by Acumen Health Research Institute, including demographic characteristics, general health-related quality of life (Veterans RAND derived mental and physical health composite scores), depression (PHQ 9-item), anxiety (GAD 7-item), comorbid conditions (CCI), health resource utilization, and perceptions, knowledge, and use of psychedelics. Multivariate and descriptive statistics were used to describe participant characteristics. Correlation analysis assessed anxiety and depression scores across groups. Mean anxiety and depression scores were compared using ANOVA and Tukey’s HSD. A multivariate linear regression model controlling for past-year depression, past-year anxiety, age, region, ethnicity, sex, educational attainment, employment, and psychedelic use predicted mental health composite scores (MCS).ResultsOf the 6,869 participants included in the dataset, 256 (3.7%) reported using psychedelics in the last 12 months. Of those using psychedelics, 122 (47.7%) reported PM use and 134 (52.3%) reported MP use. All psychedelic users reported lower MCS and higher levels of anxiety and depression relative to non-users (those who said they had not used psychedelics in the past year). The lowest mental health scores were reported in the MP users followed by the PM users (higher MCS corresponded to better mental health). When controlling for confounding characteristics including past-year anxiety and depression, disparities in mental health scores persisted between those with any psychedelic use and the non-psychedelic group (p<0.001).ConclusionThis paper extends previous work describing the association between psychedelic use and mental health, controlling for confounding mental health factors such as comorbid anxiety and depression. These results suggest psychedelic users may have poorer mental health than their non-using counterparts in certain contexts and emphasize the need for future research in this field. Both non-adjusted and adjusted analyses demonstrate lower mental health scores for PM and MP users relative to non-psychedelic users. These differential effects highlight the need for further detailed, population-based research on the use of exclusive psilocybin and on psychedelics in combination.https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1508811/fullpsychedelicspsilocybinmental healthanxietydepressionpsychedelic mushroom
spellingShingle Sofia Abramsky-Sze
Elliot Marseille
Richard Matzopoulos
Richard Matzopoulos
Robert Morlock
Leonard Lerer
Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021
Frontiers in Psychiatry
psychedelics
psilocybin
mental health
anxiety
depression
psychedelic mushroom
title Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021
title_full Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021
title_fullStr Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021
title_full_unstemmed Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021
title_short Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020–2021
title_sort characteristics and mental health of psychedelic mushroom and multi psychedelic users relative to non psychedelic users in american adults 2020 2021
topic psychedelics
psilocybin
mental health
anxiety
depression
psychedelic mushroom
url https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1508811/full
work_keys_str_mv AT sofiaabramskysze characteristicsandmentalhealthofpsychedelicmushroomandmultipsychedelicusersrelativetononpsychedelicusersinamericanadults20202021
AT elliotmarseille characteristicsandmentalhealthofpsychedelicmushroomandmultipsychedelicusersrelativetononpsychedelicusersinamericanadults20202021
AT richardmatzopoulos characteristicsandmentalhealthofpsychedelicmushroomandmultipsychedelicusersrelativetononpsychedelicusersinamericanadults20202021
AT richardmatzopoulos characteristicsandmentalhealthofpsychedelicmushroomandmultipsychedelicusersrelativetononpsychedelicusersinamericanadults20202021
AT robertmorlock characteristicsandmentalhealthofpsychedelicmushroomandmultipsychedelicusersrelativetononpsychedelicusersinamericanadults20202021
AT leonardlerer characteristicsandmentalhealthofpsychedelicmushroomandmultipsychedelicusersrelativetononpsychedelicusersinamericanadults20202021